Cargando…

On Target: CYFRA 21-1 as an Idiopathic Pulmonary Fibrosis Biomarker

Detalles Bibliográficos
Autores principales:	Spagnolo, Paolo, Oldham, Justin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2022
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875889/ https://www.ncbi.nlm.nih.gov/pubmed/35446243 http://dx.doi.org/10.1164/rccm.202203-0474ED

Ejemplares similares

CYFRA21-1 is a more sensitive biomarker to assess the severity of pulmonary alveolar proteinosis
por: Bai, Jiu-Wu, et al.
Publicado: (2022)

Word Embedding Reveals Cyfra 21-1 as a Biomarker for Chronic Obstructive Pulmonary Disease
por: Heo, Jeongwon, et al.
Publicado: (2021)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
por: Oldham, Justin M., et al.
Publicado: (2017)

Genome-Wide Association Studies in Idiopathic Pulmonary Fibrosis: Bridging the Gap between Sequence and Consequence
por: Spagnolo, Paolo, et al.
Publicado: (2020)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Clinical significance of serum CYFRA 21-1 in gastric cancer.
por: Nakata, B., et al.
Publicado: (1996)

CYFRA 21-1 in urine: a diagnostic marker for endometriosis?
por: Gjavotchanoff, Risto
Publicado: (2015)

Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma
por: He, Ying, et al.
Publicado: (2017)

Evaluation of serum cyfra21 in patients with pleural effusion
por: Azimi, Q, et al.
Publicado: (2012)

Lung Microbiome in Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
por: Amati, Francesco, et al.
Publicado: (2022)

The Management of Patients With Idiopathic Pulmonary Fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2018)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

Diagnostic and Prognostic Significance of Serum Biomarkers – Serum Amyloid A and CYFRA 21-1 in Lung Cancer
por: Dhanurdhar, Yera, et al.
Publicado: (2023)

Diagnostic Value of CYFRA 21-1 in the Cerebrospinal Fluid for Leptomeningeal Metastasis
por: Zhang, Zhen, et al.
Publicado: (2017)

CYFRA 21-1 and Placental Growth Factor as Screening Markers for Endometriosis
por: Cho, Hye-yon, et al.
Publicado: (2019)

Recent advances in the genetics of idiopathic pulmonary fibrosis
por: Spagnolo, Paolo, et al.
Publicado: (2023)

State of the Art in Idiopathic Pulmonary Fibrosis
por: El Agha, Elie, et al.
Publicado: (2022)

Idiopathic pulmonary fibrosis: moving forward
por: Richeldi, Luca
Publicado: (2015)

Update on therapeutic management of idiopathic pulmonary fibrosis
por: Tzouvelekis, Argyris, et al.
Publicado: (2015)

Environmental Causes of Idiopathic Pulmonary Fibrosis
por: Gandhi, Sheiphali, et al.
Publicado: (2023)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Autophagy in Idiopathic Pulmonary Fibrosis: Predisposition of the Aging Lung to Fibrosis?
por: Zmijewski, Jaroslaw W., et al.
Publicado: (2022)

CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.
por: Tempfer, C., et al.
Publicado: (1998)

Increases in Serum CYFRA21-1 Concentration during Successful Treatment with Crizotinib
por: Kanaji, Nobuhiro, et al.
Publicado: (2014)

Evaluation of CYFRA 21.1 as a Dedifferentiation Marker of Advanced Thyroid Cancer
por: Malapure, Sumeet Suresh, et al.
Publicado: (2020)

Role of Serum CYFRA 21-1 in Diagnosis and Prognostic in Colorectal Liver Metastases
por: Li, Shirong, et al.
Publicado: (2023)

Role of serum cytokeratin 19 fragment (Cyfra 21.1) as a prognostic biomarker in patients with differentiated thyroid cancer
por: Giovanella, L., et al.
Publicado: (2017)

B Cells in Idiopathic Pulmonary Fibrosis: Targeting Immune Cells with Antifibrotic Agents
por: Roman, Jesse, et al.
Publicado: (2021)

Lung function trajectories in patients with idiopathic pulmonary fibrosis
por: Neely, Megan L, et al.
Publicado: (2023)

Toward Early Detection of Idiopathic Pulmonary Fibrosis
por: Schupp, Jonas Christian, et al.
Publicado: (2019)

Idiopathic pulmonary fibrosis management: caring is sparing
por: Nava, Stefano, et al.
Publicado: (2020)

Current and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
por: Bonella, Francesco, et al.
Publicado: (2023)

Prognostic Role of Serum Cytokeratin-19 Fragment (CYFRA 21-1) in Patients with Hepatocellular Carcinoma
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Evaluation of pleural CYFRA 21-1 and carcinoembryonic antigen in the diagnosis of malignant pleural effusions.
por: Salama, G., et al.
Publicado: (1998)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Elevated serum CYFRA 21‐1 level as a diagnostic marker for thymic carcinoma
por: Shiiya, Haruhiko, et al.
Publicado: (2021)

ATP12A: Connecting Mucus and Fibrosis in Idiopathic Pulmonary Fibrosis
por: Zabner, Joseph, et al.
Publicado: (2023)

Diagnostic and Prognostic Potential of Biomarkers CYFRA 21.1, ERCC1, p53, FGFR3 and TATI in Bladder Cancers
por: Matuszczak, Milena, et al.
Publicado: (2020)

Blood Biomarkers in Idiopathic Pulmonary Fibrosis
por: Guiot, Julien, et al.
Publicado: (2017)

Molecular pathways in idiopathic pulmonary fibrosis pathogenesis: Transcending barriers to optimally targeted pharmacotherapies
por: Strykowski, Rachel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jpjtg26jjpu2cdevvc9i8s8c0o